CN116298309B - 成对的二分免疫受体多核苷酸的高通量克隆及其应用 - Google Patents

成对的二分免疫受体多核苷酸的高通量克隆及其应用 Download PDF

Info

Publication number
CN116298309B
CN116298309B CN202310118607.9A CN202310118607A CN116298309B CN 116298309 B CN116298309 B CN 116298309B CN 202310118607 A CN202310118607 A CN 202310118607A CN 116298309 B CN116298309 B CN 116298309B
Authority
CN
China
Prior art keywords
cells
cell
tcr
tcrs
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310118607.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116298309A (zh
Inventor
陈曦
伊利·波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Root Path Genomics Inc
Original Assignee
Root Path Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Root Path Genomics Inc filed Critical Root Path Genomics Inc
Priority to CN202310118607.9A priority Critical patent/CN116298309B/zh
Publication of CN116298309A publication Critical patent/CN116298309A/zh
Application granted granted Critical
Publication of CN116298309B publication Critical patent/CN116298309B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202310118607.9A 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用 Active CN116298309B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310118607.9A CN116298309B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862718227P 2018-08-13 2018-08-13
US62/718,227 2018-08-13
US201862725842P 2018-08-31 2018-08-31
US62/725,842 2018-08-31
US201862732898P 2018-09-18 2018-09-18
US62/732,898 2018-09-18
US201962818355P 2019-03-14 2019-03-14
US62/818,355 2019-03-14
US201962823831P 2019-03-26 2019-03-26
US62/823,831 2019-03-26
CN201980067485.7A CN112840031B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用
PCT/US2019/046170 WO2020036875A1 (en) 2018-08-13 2019-08-12 High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
CN202310118607.9A CN116298309B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980067485.7A Division CN112840031B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用

Publications (2)

Publication Number Publication Date
CN116298309A CN116298309A (zh) 2023-06-23
CN116298309B true CN116298309B (zh) 2024-04-02

Family

ID=69525770

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310118607.9A Active CN116298309B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用
CN201980067485.7A Active CN112840031B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用
CN202310093858.6A Withdrawn CN116144706A (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980067485.7A Active CN112840031B (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用
CN202310093858.6A Withdrawn CN116144706A (zh) 2018-08-13 2019-08-12 成对的二分免疫受体多核苷酸的高通量克隆及其应用

Country Status (11)

Country Link
US (2) US11208457B2 (https=)
EP (1) EP3837373B1 (https=)
JP (2) JP7227374B2 (https=)
KR (2) KR102543325B1 (https=)
CN (3) CN116298309B (https=)
AU (1) AU2019322834B2 (https=)
CA (1) CA3108439A1 (https=)
IL (2) IL294471B2 (https=)
MX (1) MX2021001763A (https=)
SG (1) SG11202101371TA (https=)
WO (1) WO2020036875A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
CN116298309B (zh) 2018-08-13 2024-04-02 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
US20210363543A1 (en) * 2018-10-30 2021-11-25 Nantbio, Inc. Self Replicating RNA System
WO2020206238A2 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
WO2023091420A2 (en) * 2021-11-16 2023-05-25 TCR2 Therapeutics Inc. Compositions and methods for t cell engineering
WO2023096890A1 (en) * 2021-11-24 2023-06-01 Rootpath Genomics, Inc. Compositions and methods for polynucleotide assembly
CN115029341A (zh) * 2022-05-23 2022-09-09 立凌生物制药(苏州)有限公司 一种快速克隆配对tcr序列检测方法及其应用
WO2023179795A1 (zh) * 2022-03-25 2023-09-28 立凌生物制药(苏州)有限公司 一种快速且简便地获得正确配对tcr的方法以及获得的tcr
CN114891779A (zh) * 2022-03-31 2022-08-12 立凌生物制药(苏州)有限公司 一种克隆tcr序列的检测方法及其应用
CN115725710A (zh) * 2022-08-09 2023-03-03 立凌生物制药(苏州)有限公司 一种快速克隆肿瘤反应性tcr的方法及其应用
WO2024077185A2 (en) * 2022-10-06 2024-04-11 The Regents Of The University Of California Core-shell hydrogel particles with tunable porosity for digital nucleic acid assays
WO2024206549A2 (en) * 2023-03-29 2024-10-03 Cellicure, Inc. Engineered immune cells and use thereof
CN116913417B (zh) * 2023-04-07 2025-11-28 四川大学 一种dna结合小分子高通量筛选及表征方法
JP2025071533A (ja) * 2023-10-23 2025-05-08 美洛生物科技股▲ふん▼有限公司 新型誘導細胞質インビトロ転写様組成物およびその関連ワクチン医薬設計
JP2025187393A (ja) * 2024-06-13 2025-12-25 株式会社日立製作所 Ｔ細胞受容体（ｔｃｒ）またはｂ細胞受容体（ｂｃｒ）の遺伝子検査方法および遺伝子検査キット

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
CN107002076A (zh) * 2014-09-15 2017-08-01 阿布维特罗有限责任公司 高通量核苷酸文库测序
CN107849560A (zh) * 2015-04-27 2018-03-27 阿布维特罗有限责任公司 对治疗剂和疾病特异性抗原进行测序、确定、配对和验证的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6607878B2 (en) 1997-10-06 2003-08-19 Stratagene Collections of uniquely tagged molecules
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
JP2004537313A (ja) 2001-07-31 2004-12-16 クローンテック ラボラトリーズ インク． 細胞内のプロテアーゼ活性を検出する方法
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
MX2008000985A (es) 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
US9029085B2 (en) 2007-03-07 2015-05-12 President And Fellows Of Harvard College Assays and other reactions involving droplets
US8454906B2 (en) 2007-07-24 2013-06-04 The Regents Of The University Of California Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions
EP3150724A1 (en) 2008-12-19 2017-04-05 President and Fellows of Harvard College Particle-assisted nucleic acid sequencing
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP3461910B1 (en) 2012-04-19 2020-08-26 Life Technologies Corporation Nucleic acid amplification
US20150005199A1 (en) 2012-08-14 2015-01-01 10X Technologies, Inc. Compositions and methods for sample processing
US20150005200A1 (en) 2012-08-14 2015-01-01 10X Technologies, Inc. Compositions and methods for sample processing
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US20140378345A1 (en) 2012-08-14 2014-12-25 10X Technologies, Inc. Compositions and methods for sample processing
AU2013302756C1 (en) 2012-08-14 2018-05-17 10X Genomics, Inc. Microcapsule compositions and methods
NZ724320A (en) * 2014-03-14 2022-05-27 Adaptimmune Ltd Tcr libraries
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US20150298091A1 (en) 2014-04-21 2015-10-22 President And Fellows Of Harvard College Systems and methods for barcoding nucleic acids
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
BR112017008877A2 (pt) 2014-10-29 2018-07-03 10X Genomics Inc métodos e composições para sequenciamento de ácido nucleico-alvo
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
KR20190006952A (ko) * 2016-03-31 2019-01-21 라이언 티씨알 피티이. 리미티드 외인성 바이러스-특이적 t 세포 수용체 (tcr)를 발현하는 비-활성화된 t 세포
WO2017177217A2 (en) * 2016-04-08 2017-10-12 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
JP2020503883A (ja) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
US20200231974A1 (en) 2017-07-18 2020-07-23 Genovie Ab A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames
WO2019126466A1 (en) 2017-12-22 2019-06-27 Rootpath Genomics, Inc. Compositions and methods for barcoding
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
CN116298309B (zh) 2018-08-13 2024-04-02 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
WO2020206238A2 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
EP4061487A4 (en) 2019-11-19 2023-12-20 Rootpath Genomics, Inc. COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
CN107002076A (zh) * 2014-09-15 2017-08-01 阿布维特罗有限责任公司 高通量核苷酸文库测序
CN107849560A (zh) * 2015-04-27 2018-03-27 阿布维特罗有限责任公司 对治疗剂和疾病特异性抗原进行测序、确定、配对和验证的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+T cell epitope;InYoung Song等;《Nature Structural & Molecular Biology》;第24卷;第395–406页 *
Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy;Lorenz, FKM 等;《Human Gene Therapy》;第28卷(第12期);第1158-1168页 *

Also Published As

Publication number Publication date
IL294471A (en) 2022-09-01
JP7475506B2 (ja) 2024-04-26
MX2021001763A (es) 2021-04-19
SG11202101371TA (en) 2021-03-30
US12098181B2 (en) 2024-09-24
IL294471B1 (en) 2024-03-01
US20220135641A1 (en) 2022-05-05
CN116144706A (zh) 2023-05-23
US20210171600A1 (en) 2021-06-10
IL294471B2 (en) 2024-07-01
AU2019322834B2 (en) 2024-07-18
KR20230088518A (ko) 2023-06-19
JP7227374B2 (ja) 2023-02-21
EP3837373A1 (en) 2021-06-23
CN116298309A (zh) 2023-06-23
KR102543325B1 (ko) 2023-06-13
US11208457B2 (en) 2021-12-28
KR20210057043A (ko) 2021-05-20
CN112840031B (zh) 2023-03-24
CN112840031A (zh) 2021-05-25
CA3108439A1 (en) 2020-02-20
JP2023058615A (ja) 2023-04-25
EP3837373B1 (en) 2024-06-12
WO2020036875A1 (en) 2020-02-20
JP2021534245A (ja) 2021-12-09
EP3837373A4 (en) 2022-07-06
IL280682A (en) 2021-03-25
AU2019322834A1 (en) 2021-03-18
IL280682B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
CN116298309B (zh) 成对的二分免疫受体多核苷酸的高通量克隆及其应用
ES2948133T3 (es) Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
AU2025200842A1 (en) Treatment of cancer using anti-CD19 chimeric antigen receptor
TWI719946B (zh) 使用ｃｄ１２３嵌合抗原受體治療癌症
EP3172234B1 (en) Treatment of cancer using a cd33 chimeric antigen receptor
ES2955408T3 (es) Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos
CN114945382A (zh) Cd19和cd22嵌合抗原受体及其用途
EP3368689A2 (en) Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
Hocevar et al. PEGylated gold nanoparticles target age-associated B cells in vivo
CA3161775A1 (en) Compositions and methods for t-cell receptor identification
Tretbar et al. Non-viral vectors for chimeric antigen receptor immunotherapy
EP4326308A2 (en) Nanoparticles for antigen-specific cell programming and uses thereof
CN119677842A (zh) 人工合成肿瘤浸润淋巴细胞
HK40052150B (en) High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
HK40052150A (en) High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
KR20260051061A (ko) Cd19-표적화 car t 세포 요법
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
HK1231901A1 (en) Treatment of cancer using a cd33 chimeric antigen receptor
HK1231901B (en) Treatment of cancer using a cd33 chimeric antigen receptor
HK1228445B (en) Treatment of cancer using anti-cd19 chimeric antigen receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant